Feb 16, 2018   SOURCE: PR NewsWire

Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline

DUBLIN, Feb. 16, 2018 /PRNewswire/ --

The "Chronic Myeloid Leukemia (CML)" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Market Snapshot

    --  The CML market will experience a short period of growth followed by a
        decline in sales due to the onset of generic competition.
    --  The largest unmet needs in CML are overcoming TKI resistance and
        addressing patients with accelerated or blast phase disease.
    --  The number of incident chronic myeloid leukemia cases is expected to
        increase by 25% over the next 20 years.
    --  Generic imatinib will dominate first-line treatment as Sprycel and
        Tasigna compete for market share in the second line.
    --  Asciminib is currently the primary candidate in the pipeline, and may
        benefit patients progressing on available TKIs.

Key Topics Covered:

Forecast: Chronic Myeloid Leukemia

    --  Executive Summary
    --  Market Overview And Trends
    --  Market Definition And Methodology
    --  Asciminib
    --  Bosulif (Bosutinib)
    --  Gleevec (Imatinib)
    --  Iclusig (Ponatinib)
    --  Sprycel (Dasatinib)
    --  Synribo (Omacetaxine Mepesuccinate)
    --  Tasigna (Nilotinib)
    --  Primary Research Methodology

Treatment: Chronic Myeloid Leukemia

    --  Executive Summary
    --  Primary Research Methodology
    --  Disease Definition And Diagnosis
    --  Patient Segmentation
    --  Current Treatment Options
    --  Prescribing Trends

Epidemiology: Chronic Myeloid Leukemia In The Us, Japan, And 5EU

    --  Executive Summary
    --  Disease Background
    --  Sources And Methodology
    --  Forecast
    --  Epidemiologist Insight
    --  Strengths And Limitations
    --  Bibliography
    --  Appendix: Additional Sources

Marketed Drugs: Chronic Myeloid Leukemia

    --  Executive Summary
    --  Product Overview
    --  Product Profile: Bosulif
    --  Product Profile: Gleevec
    --  Product Profile: Iclusig
    --  Product Profile: Sprycel
    --  Product Profile: Synribo
    --  Product Profile: Tasigna

Pipeline: Chronic Myeloid Leukemia

    --  Executive Summary
    --  Clinical Pipeline Overview
    --  Comparator Therapy
    --  Product Profile (Late Stage): Asciminib

For more information about this report visit https://www.researchandmarkets.com/research/k7kr9g/global_chronic?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-chronic-myeloid-leukemia-cml-market-report-2017-focus-on-forecasts-treatment-epidemiology-marketed-drugs--pipeline-300600012.html

SOURCE Research and Markets